Close menu




May 12th, 2022 | 11:12 CEST

BioNTech, BYD and Desert Gold: Shares for the rebound

  • Gold
  • Electromobility
  • Biotechnology
Photo credits: pixabay.com

Is the rebound coming? After the heavy price losses of recent days and weeks, the market seems ripe for a countermovement. However, this would require a little more volume in the market. But then, especially companies that have not disappointed operationally should profit. BioNTech, for example, belongs to this group. The Company has published convincing figures, and analysts see up to 50% price potential. BYD's share price should also pick up speed again. Finally, the rapid shift to electric pureplay seems to be succeeding and HSBC has raised the price target. Gold was not a safe haven in the current correction. But it is worth looking at bombed-out stocks here as well. Desert Gold Ventures is one of them. The explorer has started a new drill program and secured financing.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , BYD CO. LTD H YC 1 | CNE100000296 , DESERT GOLD VENTURES | CA25039N4084

Table of contents:


    Desert Gold secures financing and commences drilling program

    The stock of Desert Gold Ventures Inc. has fallen from EUR 0.11 to EUR 0.06 within a few weeks. As a result, this could mean a good entry opportunity. Next week, management will present at the International Investment Forum (IIF). Registration for the digital investor conference is free of charge here. Operationally, things are going positively for the Canadian gold explorer. The Company has just received about CAD 1.5 million through a successful private placement. With this, the projects can be advanced. After the latest positive drill results, the stock shot up to CAD 0.20.

    The funding will allow Desert Gold to move forward with its flagship SMSZ project in western Mali, which is close to a large Barrick Gold mine. New drilling has started. With this, the Canadians want to follow up on the promising results so far: 1.94 g/t gold over 30m and 2.75 g/t gold over 12m. In the current year, several drill passes with a total length of 20,000 meters are to take place and provide newsflow. Should Desert Gold succeed in building on its previous results, the current valuation of around EUR 10 million would appear to be anything but too high.

    BioNTech with up to 50% price potential

    The BioNTech share also seems to have room for improvement. The German biotech leader was able to convince with quarterly figures. In the first three months of 2022, the Company tripled its sales and profits compared to the previous year. The sales forecast for the full year of EUR 13 billion to EUR 17 billion was also confirmed. Goldman Sachs left its rating on BioNTech shares at "Neutral" after the numbers. The price target is USD 255. Based on the Corona vaccine, BioNTech's numbers were strong and beat analysts' estimates. Study data on the pediatric vaccine and several Omicron-specific variants are expected in the coming weeks. BioNTech also beat estimates from JPMorgan. The analysts have a price target of USD 183. Even if the Corona vaccine were to become less important, the Company is well-positioned in the oncology segment. For Jefferies, the fair value of BioNTech stock is USD 230. The analysts expect to see initial results on a flu vaccine later this year. Currently, BioNTech shares are trading at around USD 144 and EUR 138, respectively. Therefore, the price targets are significantly above the current level of the share. Why the assessments are still only "Hold" remains the analysts' secret.

    BYD: HSBC raises price target

    The BYD share benefits from a recommendation by HSBC. The analysts have raised the price target slightly from HKD 332 to HKD 342 and rate the stock as a buy - the share is currently trading at around HKD 233. Due to product strength in NEVs (hybrid and all-electric vehicles), sales volume and profit should pick up in 2022/2023. As one of China's largest electric car manufacturers, the Company announced that it would no longer produce pure internal combustion vehicles but only plug-in hybrids and pure electric cars. In addition, the Company produces the batteries itself and also has buses in its range. BYD is doing well with this: in the first quarter of 2022, sales increased by more than 60%. Profits even increased by 241%. The growth driver is the NEV sector. In the first three months, BYD sold 286,329 new energy vehicles - 400% more than in the same period last year. The model offensive has also taken off: Additional variants of the best-selling "Han" are available, and BYD plans to present a further 10 electric models in the current year.


    The numbers are right for BYD and BioNTech, and analysts see significant upside potential. Desert Gold is anything but highly valued. If the drilling results are positive, the share price should have considerable upside potential.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Nico Popp on February 2nd, 2023 | 18:04 CET

    Bulging pipeline at BioNTech, Cardiol Therapeutics - what is the problem at Aurora Cannabis?

    • Biotechnology
    • Cannabis
    • Cancer

    He who heals is right. It is not quite that simple with active ingredients that are about to be approved. Drugs and vaccines must undergo extensive studies and, last but not least, have to prevail against the existing competition. We look at the pipelines of three hot stocks and venture a forecast: Where is the greatest potential for investors?

    Read

    Commented by Stefan Feulner on February 1st, 2023 | 20:29 CET

    BioNTech, Defence Therapeutics, PAION - All dams broken

    • Biotechnology

    High price fluctuations due to approvals or successful test results are more the norm than the rule in the biotechnology sector. It is common for smaller stocks, in particular, to multiply within a few days. For example, the shares of Ambrx Biopharma increased by a whopping 1,000% within just one day, while the German biotech hopeful PAION doubled in price within a week. The next candidates for above-average performances are already waiting in the wings.

    Read

    Commented by Armin Schulz on February 1st, 2023 | 20:22 CET

    Altech Advanced Materials, Mercedes-Benz Group, NIO - Electric mobility on the verge of a revolution

    • Innovations
    • Technology
    • Electromobility

    Electric cars are becoming increasingly popular as a sustainable mode of transportation. As technology improves, this type of vehicle is becoming more attractive to investors looking for an environmentally friendly option. However, some important issues still need to be addressed before electric cars become a natural alternative for most people. Chief issues are battery charging times, limited range, and safety. Today, we look at Altech Advanced Materials, a company that has developed a solution to the problems, and look at the current status of two automakers.

    Read